Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.240
0.00 (0.00%)
At close: Sep 17, 2026, 4:00 PM EDT
2.300
+0.060 (2.68%)
After-hours: Sep 17, 2026, 6:31 PM EDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K in the half year ending June 30, 2026, a decrease of -36.08%. This brings the company's revenue in the last twelve months to $405.00K, down -27.68% year-over-year. In the year 2025, Can-Fite BioPharma had annual revenue of $405.00K, down -39.91%.
Revenue (ttm)
$405.00K
Revenue Growth
-27.68%
P/S Ratio
12.21
Revenue / Employee
$81,000
Employees
5
Market Cap
4.95M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 405.00K | -269.00K | -39.91% |
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | -200.00 | -0.12% |
| Dec 31, 2015 | 165.20K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Lexaria Bioscience | 194.00K |
| Jupiter Neurosciences | 64.69K |
| Cardio Diagnostics Holdings | 14.45K |
| Pulmatrix | 3.00K |
| Creative Medical Technology Holdings | 3.00K |
CANF News
- Just now - Can-Fite BioPharma Earnings release: Q2 2026 - Filings
- 8 days ago - Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation - GlobeNewsWire
- 9 days ago - Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study - GlobeNewsWire
- 15 days ago - Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges - Nasdaq
- 15 days ago - CANF Looks 45.6% Undervalued on GF Value⢠Despite Challenging Fundamentals - GuruFocus
- 15 days ago - Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - GlobeNewsWire
- 15 days ago - Can-Fite reports longer-than-anticipated survival observed in Namodenoson study - TheFly
- 15 days ago - Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study - GlobeNewsWire